Barclays set a €81.00 ($94.19) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report released on Thursday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
FME has been the topic of several other reports. Goldman Sachs Group cut Micro Focus International from a neutral rating to a sell rating in a research report on Tuesday, July 16th. HSBC set a €101.00 ($117.44) price objective on Grenke and gave the company a buy rating in a research report on Thursday, April 25th. Jefferies Financial Group reaffirmed a buy rating and set a GBX 99 ($1.29) price objective on shares of in a research report on Friday, June 28th. Independent Research set a €74.00 ($86.05) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research report on Monday, June 17th. Finally, Deutsche Bank set a €230.00 ($267.44) price objective on adidas and gave the company a neutral rating in a research report on Tuesday, May 7th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA presently has an average rating of Buy and an average target price of €82.57 ($96.01).
Fresenius Medical Care AG & Co. KGaA stock opened at €67.00 ($77.91) on Thursday. The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. Fresenius Medical Care AG & Co. KGaA has a one year low of €55.44 ($64.47) and a one year high of €91.74 ($106.67). The stock has a market capitalization of $20.45 billion and a PE ratio of 10.43. The firm’s fifty day simple moving average is €68.38.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: Why are gap-down stocks important?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.